{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-058584","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.803340+00:00","generated_at":"2026-06-05T03:49:48.469074+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seres Therapeutics Q4/FY2023: VOWST net sales $10.4M Q4, $19.6M YTD; net loss narrows to $113.7M","bullets":["Net loss of $113.7M for FY2023 versus $250.2M prior year; Q4 net loss $41.2M vs $68.8M.","VOWST net sales $10.4M in Q4, $19.6M since June launch; 2,833 enrollment forms, 2,015 new patient starts.","Restructuring expected to save $75-85M annually; cash and equivalents $128.0M at year-end.","SER-155 Phase 1b Cohort 2 data readout anticipated in Q3 2024; Fast Track designation awarded.","Appointed Marella Thorell as EVP/CFO following retirement of David Arkowitz."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-058584","json":"https://secwatch.observer/filing/0001193125-24-058584.json","markdown":"https://secwatch.observer/filing/0001193125-24-058584.md","text":"https://secwatch.observer/filing/0001193125-24-058584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/0001193125-24-058584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/d806486d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:49:48.469074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97519a66267676ed8fcf257fbd2af657a6bcc49c","claim":"Seres Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: revenue $10.4 million, net income $41.2 million.","evidence_excerpt":"Seres reported a net loss of $41.2 million for the fourth quarter of 2023, as compared to a net loss of $68.8 million for the same period in 2022. Net sales of VOWST for the fourth quarter and full year 2023, were $10.4 million and $19.6 million, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312524058584/0001193125-24-058584-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$10.4 million"},{"label":"Net income","value":"$41.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}